Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
about
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.Emerging drugs for overactive bladder.Delivery methods for drugs used in the treatment of overactive bladder.A drug safety evaluation of mirabegron in the management of overactive bladder.Treatment of Concomitant OAB and BPH.Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.Tolerability and persistence in a large, prospective case series of women prescribed mirabegron.Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.Future directions in overactive bladder treatment: Personalized medicine can be applied?Recent advances in pharmacological management of urinary incontinence.Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist
P2860
Q33863110-143564A3-488A-465C-BCFE-F3A5C8C7A6FBQ36089975-003F2372-6798-41EF-8E86-4F1F66515CA6Q38584641-C8F2B66D-E1C9-4FC8-830B-ABD338822DF5Q38665319-655EC62B-764F-496C-B34D-3E0CF47EDCCDQ38776115-B7358023-FE16-4AF9-82D5-79859FFADA18Q39090324-8D7C4AB0-CE3F-4EB7-9168-3726332D428EQ39667385-C847747B-A143-4B06-A190-F277106EE8FFQ40068468-11A00116-B68C-4F20-9F38-D1BFDC05B2DCQ40936665-32EDB62A-D905-4CFB-B0D9-4723EF25A2FDQ43213161-343A079B-A1FD-4CFF-BF05-80607045B663Q48247040-4CF984F4-6897-43F0-92AC-0ED366958847Q57106873-BAFE9F0C-B626-4FDD-A74F-17DC93BC8FA8
P2860
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Mirabegron 50 mg once-daily fo ...... lity over 12 weeks and 1 year.
@en
type
label
Mirabegron 50 mg once-daily fo ...... lity over 12 weeks and 1 year.
@en
prefLabel
Mirabegron 50 mg once-daily fo ...... lity over 12 weeks and 1 year.
@en
P2093
P2860
P356
P1476
Mirabegron 50 mg once-daily fo ...... lity over 12 weeks and 1 year.
@en
P2093
David Mitcheson
Emad Siddiqui
Mary Beth Blauwet
Moses Huang
Steven A Kaplan
Vik Khullar
P2860
P304
P356
10.1111/IJU.12568
P577
2014-08-04T00:00:00Z